RELAPSED CANCER
Clinical trials for RELAPSED CANCER explained in plain language.
Never miss a new study
Get alerted when new RELAPSED CANCER trials appear
Sign up with your email to follow new studies for RELAPSED CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug targets deadly brain cancer in early trial
Disease control Recruiting nowThis study tests a new drug called LMP744 in 40 adults whose glioblastoma (a type of brain cancer) has come back after standard treatment. The drug is given through a vein for 5 days each month for up to a year. The goal is to see if it can shrink tumors or slow their growth.
Matched conditions: RELAPSED CANCER
Phase: PHASE1, PHASE2 • Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) • Aim: Disease control
Last updated May 26, 2026 04:43 UTC
-
New cocktail aims to tame Hard-to-Treat myeloma
Disease control Recruiting nowThis study tests a combination of four drugs (isatuximab, belantamab mafodotin, pomalidomide, and dexamethasone) in 50 adults with multiple myeloma that has come back or stopped responding to prior treatments. The main goal is to see how many patients' tumors shrink or disappear.…
Matched conditions: RELAPSED CANCER
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated May 26, 2026 04:42 UTC
-
New combo therapy offers hope for hard-to-treat lymphoma patients
Disease control Recruiting nowThis study tests a new drug combination (epcoritamab plus chemotherapy) in 32 adults whose large B-cell lymphoma has returned or not responded to prior treatment. The goal is to see if this approach can shrink tumors and help patients become eligible for a stem cell transplant or…
Matched conditions: RELAPSED CANCER
Phase: PHASE2 • Sponsor: Dipenkumar Modi • Aim: Disease control
Last updated May 26, 2026 04:42 UTC
-
New hope for hard-to-treat blood cancers: experimental drug combo enters human trials
Disease control Recruiting nowThis study tests a new drug called BGB-16673, which breaks down a protein that helps cancer cells grow, combined with other treatments. It is for people with B-cell blood cancers (like lymphoma) that have returned or not responded to prior therapy. The study will enroll about 80 …
Matched conditions: RELAPSED CANCER
Phase: PHASE1, PHASE2 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated May 26, 2026 04:41 UTC
-
Could multiple myeloma treatment move out of the hospital?
Disease control Recruiting nowThis study looks at whether a cancer drug called teclistamab can be given safely in an outpatient clinic instead of the hospital for people with relapsed or refractory multiple myeloma. It involves 15 adults who have already tried at least three other treatments. The goal is to c…
Matched conditions: RELAPSED CANCER
Phase: PHASE4 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated May 26, 2026 04:40 UTC
-
Promising combo tackles Hard-to-Treat brain cancer
Disease control Recruiting nowThis study tests a combination of two drugs (zanubrutinib and pemetrexed) followed by zanubrutinib alone for people with a type of brain lymphoma that has returned or not responded to prior treatment. The goal is to see how well the treatment shrinks tumors and controls the disea…
Matched conditions: RELAPSED CANCER
Phase: PHASE2 • Sponsor: Baptist Health South Florida • Aim: Disease control
Last updated May 26, 2026 04:35 UTC
-
New hope for stubborn leukemia: three-drug combo enters human trials
Disease control Recruiting nowThis study tests whether adding a new drug called roginolisib to two standard drugs (venetoclax and rituximab) is safe and works better for people with CLL that has come back or not responded to prior treatments. About 64 adults who have already tried at least two other therapies…
Matched conditions: RELAPSED CANCER
Phase: PHASE1, PHASE2 • Sponsor: Jennifer R. Brown, MD, PhD • Aim: Disease control
Last updated May 26, 2026 04:32 UTC
-
New drug cocktail shows promise for Hard-to-Treat brain cancer
Disease control Recruiting nowThis study tests a combination of three drugs (pembrolizumab, ibrutinib, and rituximab) in people whose primary central nervous system lymphoma has come back or not responded to prior treatment. The goal is to see if the combo can control the cancer for at least 6 months. About 3…
Matched conditions: RELAPSED CANCER
Phase: PHASE1, PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated May 15, 2026 11:53 UTC